HCW Biologics (HCWB) Q1 2025 earnings summary

Executive summary

• Clinical-stage biopharma focused on immunotherapies for age-related and inflammatory diseases, with a pipeline including HCW9302 and HCW9206 targeting autoimmune and cancer indications.

• Achieved key milestones: FDA IND clearance for HCW9302 Phase 1 trial in alopecia areata, with trial launch expected in Q3 2025, and progress in CAR-T enabling technology HCW9206.

• Closed a $5.0 million equity offering in May 2025 to fund clinical site openings and business development for licensing immunotherapy assets.

• Delivered a technology report to WY Biotech for a $7.0 million upfront licensing fee, pending due diligence.

• Resolved major legal uncertainties via a settlement with ImmunityBio, clarifying IP rights and enabling new financing and business development strategies.

Financial highlights

• Net loss for Q1 2025 was $2.2 million, a significant improvement from $7.5 million in Q1 2024, driven by lower R&D and legal expenses.

• Revenues dropped to $5,065 in Q1 2025 from $1.1 million in Q1 2024, reflecting reduced supply sales to Wugen.

• Cash and cash equivalents were $1.1 million as of March 31, 2025, down from $4.7 million at year-end 2024.

• General and administrative expenses rose 42% year-over-year to $2.2 million, mainly due to higher salaries, bonus accruals, and increased professional fees.

• Total assets declined to $26.3 million at March 31, 2025, from $30.2 million at December 31, 2024.

Outlook and guidance

• Substantial doubt remains about the ability to continue as a going concern for the next 12 months without additional funding.

• Management is pursuing equity offerings, licensing deals, and cost reductions to address liquidity needs.

• Anticipates $7.0 million in license revenue from WY Biotech in June 2025, pending acceptance of a technology transfer report.

• Plans to ramp up business development and licensing efforts in the second half of 2025.

• Financing plan underway, but future success in securing funds is uncertain.